CoindreJ, TerrierP, GuillouL et al.. Predictive value of grade for metastasis development in the main histologic types of adult soft tissue sarcomas: a study of 1240 patients from the French Federation of Cancer Centers Sarcoma Group. Cancer2001;91:1914–1926.
CoindreJTerrierPGuillouL. Predictive value of grade for metastasis development in the main histologic types of adult soft tissue sarcomas: a study of 1240 patients from the French Federation of Cancer Centers Sarcoma Group. Cancer2001;91:1914–1926.
)| false
PfeiferJD, HillDA, O’SullivanMJ, DehnerLP. Diagnostic gold standard for soft tissue tumours: morphology or molecular genetics?Histopathology2000;37:485–500.
PfeiferJDHillDAO’SullivanMJDehnerLP. Diagnostic gold standard for soft tissue tumours: morphology or molecular genetics?Histopathology2000;37:485–500.
)| false
HillDA, O’SullivanMJ, ZhuX et al.. Practical application of molecular genetic testing as an aid to the surgical pathologic diagnosis of sarcomas: a prospective study. Am J Surg Pathol2002;26:965–977.
HillDAO’SullivanMJZhuX. Practical application of molecular genetic testing as an aid to the surgical pathologic diagnosis of sarcomas: a prospective study. Am J Surg Pathol2002;26:965–977.
)| false
SorensenPH, LynchJC, QualmanSJ et al.. PAX3-FKHR and PAX7-FKHR gene fusions are prognostic indicators in alveolar thabdomyosarcoma: a report from the Children’s Oncology Group. J Clin Oncol2002;20:2672–2679.
SorensenPHLynchJCQualmanSJ. PAX3-FKHR and PAX7-FKHR gene fusions are prognostic indicators in alveolar thabdomyosarcoma: a report from the Children’s Oncology Group. J Clin Oncol2002;20:2672–2679.
)| false
GuillouL, BenhattarJ, BonichonF et al.. Histologic grade, but not SYT-SSX fusion type, is an important prognostic factor in patients with synovial sarcoma: a multicenter, retrospective analysis. J Clin Oncol2004;22:4040–4050.
GuillouLBenhattarJBonichonF. Histologic grade, but not SYT-SSX fusion type, is an important prognostic factor in patients with synovial sarcoma: a multicenter, retrospective analysis. J Clin Oncol2004;22:4040–4050.
)| false
LadanyiM, AntonescuCR, LeungDH et al.. Impact of SYT-SSX fusion type on the clinical behavior of synovial sarcoma: a multi-institutional retrospective study of 243 patients. Cancer Res2002;62:135–140.
LadanyiMAntonescuCRLeungDH. Impact of SYT-SSX fusion type on the clinical behavior of synovial sarcoma: a multi-institutional retrospective study of 243 patients. Cancer Res2002;62:135–140.
)| false
AntonescuCR, TschernyavskySJ, DecusearaR et al.. Prognostic impact of P53 status, TLS-CHOP fusion transcript structure, and histological grade in myxoid liposarcoma: a molecular and clinicopathologic study of 82 cases. Clin Cancer Res2001;7:3977–3987.
AntonescuCRTschernyavskySJDecusearaR. Prognostic impact of P53 status, TLS-CHOP fusion transcript structure, and histological grade in myxoid liposarcoma: a molecular and clinicopathologic study of 82 cases. Clin Cancer Res2001;7:3977–3987.
)| false
GuillouL, CoindreJ, BonichonF et al.. Comparative study of the National Cancer Institute and French Federation of Cancer Centers Sarcoma Group grading systems in a population of 410 adult patients with soft tissue sarcoma. J Clin Oncol1997;15:350–362.
GuillouLCoindreJBonichonF. Comparative study of the National Cancer Institute and French Federation of Cancer Centers Sarcoma Group grading systems in a population of 410 adult patients with soft tissue sarcoma. J Clin Oncol1997;15:350–362.
)| false
KimB, ChenYL, KirschDG et al.. An effective preoperative three-dimensional radiotherapy target volume for extremity soft tissue sarcoma and the effect of margin width on local control. Int J Radiat Oncol Biol Phys2010; in press.
KimBChenYLKirschDG. An effective preoperative three-dimensional radiotherapy target volume for extremity soft tissue sarcoma and the effect of margin width on local control. Int J Radiat Oncol Biol Phys2010; in press.
)| false
FlemingJB, BermanRS, ChengSC et al.. Long-term outcome of patients with American Joint Committee on Cancer stage IIB extremity soft tissue sarcomas. J Clin Oncol1999;17:2772–2780.
FlemingJBBermanRSChengSC. Long-term outcome of patients with American Joint Committee on Cancer stage IIB extremity soft tissue sarcomas. J Clin Oncol1999;17:2772–2780.
)| false
GerrandCH, WunderJS, KandelRA et al.. Classification of positive margins after resection of soft-tissue sarcoma of the limb predicts the risk of local recurrence. J Bone Joint Surg Br2001;83:1149–1155.
GerrandCHWunderJSKandelRA. Classification of positive margins after resection of soft-tissue sarcoma of the limb predicts the risk of local recurrence. J Bone Joint Surg Br2001;83:1149–1155.
)| false
PistersPW, LeungDH, WoodruffJ et al.. Analysis of prognostic factors in 1,041 patients with localized soft tissue sarcomas of the extremities. J Clin Oncol1996;14:1679–1689.
PistersPWLeungDHWoodruffJ. Analysis of prognostic factors in 1,041 patients with localized soft tissue sarcomas of the extremities. J Clin Oncol1996;14:1679–1689.
)| false
ZagarsGK, BalloMT, PistersPW et al.. Surgical margins and reresection in the management of patients with soft tissue sarcoma using conservative surgery and radiation therapy. Cancer2003;97:2544–2553.
ZagarsGKBalloMTPistersPW. Surgical margins and reresection in the management of patients with soft tissue sarcoma using conservative surgery and radiation therapy. Cancer2003;97:2544–2553.
)| false
GhertMA, AbuduA, DriverN et al.. The indications for and the prognostic significance of amputation as the primary surgical procedure for localized soft tissue sarcoma of the extremity. Ann Surg Oncol2005;12:10–17.
GhertMAAbuduADriverN. The indications for and the prognostic significance of amputation as the primary surgical procedure for localized soft tissue sarcoma of the extremity. Ann Surg Oncol2005;12:10–17.
)| false
StojadinovicA, JaquesDP, LeungDH et al.. Amputation for recurrent soft tissue sarcoma of the extremity: indications and outcome. Ann Surg Oncol2001;8:509–518.
StojadinovicAJaquesDPLeungDH. Amputation for recurrent soft tissue sarcoma of the extremity: indications and outcome. Ann Surg Oncol2001;8:509–518.
)| false
WilliardWC, HajduSI, CasperES, BrennanMF. Comparison of amputation with limb-sparing operations for adult soft tissue sarcoma of the extremity. Ann Surg1992;215:269–275.
WilliardWCHajduSICasperESBrennanMF. Comparison of amputation with limb-sparing operations for adult soft tissue sarcoma of the extremity. Ann Surg1992;215:269–275.
)| false
DeLaneyTF, TrofimovAV, EngelsmanM, SuitHD. Advanced-technology radiation therapy in the management of bone and soft tissue sarcomas. Cancer Control2005;12:27–35.
DeLaneyTFTrofimovAVEngelsmanMSuitHD. Advanced-technology radiation therapy in the management of bone and soft tissue sarcomas. Cancer Control2005;12:27–35.
)| false
DavisA, O’SullivanB, BellR et al.. Function and health status outcomes in a randomized trial comparing preoperative and postoperative radiotherapy in extremity soft tissue sarcoma. J Clin Oncol2002;20:4472–4477.
DavisAO’SullivanBBellR. Function and health status outcomes in a randomized trial comparing preoperative and postoperative radiotherapy in extremity soft tissue sarcoma. J Clin Oncol2002;20:4472–4477.
)| false
SadoskiC, SuitH, RosenbergA et al.. Preoperative radiation, surgical margins, and local control of extremity sarcomas of soft tissues. J Surg Oncol1993;52:223–230.
SadoskiCSuitHRosenbergA. Preoperative radiation, surgical margins, and local control of extremity sarcomas of soft tissues. J Surg Oncol1993;52:223–230.
)| false
AlektiarKM, VelascoJ, ZelefskyMJ et al.. Adjuvant radiotherapy for margin-positive high-grade soft tissue sarcoma of the extremity. Int J Radiat Oncol Biol Phys2000;48:1051–1058.
AlektiarKMVelascoJZelefskyMJ. Adjuvant radiotherapy for margin-positive high-grade soft tissue sarcoma of the extremity. Int J Radiat Oncol Biol Phys2000;48:1051–1058.
)| false
CahlonO, SpiererM, BrennanMF et al.. Long-term outcomes in extremity soft tissue sarcoma after a pathologically negative re-resection and without radiotherapy. Cancer2008;112:2774–2779.
CahlonOSpiererMBrennanMF. Long-term outcomes in extremity soft tissue sarcoma after a pathologically negative re-resection and without radiotherapy. Cancer2008;112:2774–2779.
)| false
RosenbergSA, TepperJ, GlatsteinE et al.. The treatment of soft-tissue sarcomas of the extremities: prospective randomized evaluations of (1) limb-sparing surgery plus radiation therapy compared with amputation and (2) the role of adjuvant chemotherapy. Ann Surg1982;196:305–315.
RosenbergSATepperJGlatsteinE. The treatment of soft-tissue sarcomas of the extremities: prospective randomized evaluations of (1) limb-sparing surgery plus radiation therapy compared with amputation and (2) the role of adjuvant chemotherapy. Ann Surg1982;196:305–315.
)| false
BaldiniEH, GoldbergJ, JennerC et al.. Long-term outcomes after function-sparing surgery without radiotherapy for soft tissue sarcoma of the extremities and trunk. J Clin Oncol1999;17:3252–3259.
BaldiniEHGoldbergJJennerC. Long-term outcomes after function-sparing surgery without radiotherapy for soft tissue sarcoma of the extremities and trunk. J Clin Oncol1999;17:3252–3259.
)| false
O’SullivanB, DavisA, TurcotteR et al.. Five-year results of a randomized phase III trial of pre-operative vs post-operative radiotherapy in extremity soft tissue sarcoma [abstract]. J Clin Oncol2004;22(Suppl 1):Abstract 9007.
O’SullivanBDavisATurcotteR. Five-year results of a randomized phase III trial of pre-operative vs post-operative radiotherapy in extremity soft tissue sarcoma [abstract]. J Clin Oncol2004;22(Suppl 1):Abstract 9007.
)| false
YangJC, ChangAE, BakerAR et al.. Randomized prospective study of the benefit of adjuvant radiation therapy in the treatment of soft tissue sarcomas of the extremity. J Clin Oncol1998;16:197–203.
YangJCChangAEBakerAR. Randomized prospective study of the benefit of adjuvant radiation therapy in the treatment of soft tissue sarcomas of the extremity. J Clin Oncol1998;16:197–203.
)| false
WilsonAN, DavisA, BellRS et al.. Local control of soft tissue sarcoma of the extremity: the experience of a multidisciplinary sarcoma group with definitive surgery and radiotherapy. Eur J Cancer1994;30A:746–751.
WilsonANDavisABellRS. Local control of soft tissue sarcoma of the extremity: the experience of a multidisciplinary sarcoma group with definitive surgery and radiotherapy. Eur J Cancer1994;30A:746–751.
)| false
PistersPW, HarrisonLB, LeungDH et al.. Long-term results of a prospective randomized trial of adjuvant brachytherapy in soft tissue sarcoma. J Clin Oncol1996;14:859–868.
PistersPWHarrisonLBLeungDH. Long-term results of a prospective randomized trial of adjuvant brachytherapy in soft tissue sarcoma. J Clin Oncol1996;14:859–868.
)| false
AlektiarKM, BrennanMF, HealeyJH, SingerS. Impact of intensity-modulated radiation therapy on local control in primary soft-tissue sarcoma of the extremity. J Clin Oncol2008;26:3440–3444.
AlektiarKMBrennanMFHealeyJHSingerS. Impact of intensity-modulated radiation therapy on local control in primary soft-tissue sarcoma of the extremity. J Clin Oncol2008;26:3440–3444.
)| false
DemasBE, HeelanRT, LaneJ et al.. Soft-tissue sarcomas of the extremities: comparison of MR and CT in determining the extent of disease. AJR Am J Roentgenol1988;150:615–620.
DemasBEHeelanRTLaneJ. Soft-tissue sarcomas of the extremities: comparison of MR and CT in determining the extent of disease. AJR Am J Roentgenol1988;150:615–620.
)| false
SchwabJH, BolandPJ, AntonescuC et al.. Spinal metastases from myxoid liposarcoma warrant screening with magnetic resonance imaging. Cancer2007;110:1815–1822.
SchwabJHBolandPJAntonescuC. Spinal metastases from myxoid liposarcoma warrant screening with magnetic resonance imaging. Cancer2007;110:1815–1822.
)| false
TateishiU, HasegawaT, BeppuY et al.. Prognostic significance of MRI findings in patients with myxoid-round cell liposarcoma. AJR Am J Roentgenol2004;182:725–731.
TateishiUHasegawaTBeppuY. Prognostic significance of MRI findings in patients with myxoid-round cell liposarcoma. AJR Am J Roentgenol2004;182:725–731.
)| false
PorteraCAJr, HoV, PatelSR et al.. Alveolar soft part sarcoma: clinical course and patterns of metastasis in 70 patients treated at a single institution. Cancer2001;91:585–591.
PorteraCAJrHoVPatelSR. Alveolar soft part sarcoma: clinical course and patterns of metastasis in 70 patients treated at a single institution. Cancer2001;91:585–591.
)| false
FolpeAL, LylesRH, SprouseJT et al.. (F-18) fluorodeoxyglucose positron emission tomography as a predictor of pathologic grade and other prognostic variables in bone and soft tissue sarcoma. Clin Cancer Res2000;6:1279–1287.
FolpeALLylesRHSprouseJT. (F-18) fluorodeoxyglucose positron emission tomography as a predictor of pathologic grade and other prognostic variables in bone and soft tissue sarcoma. Clin Cancer Res2000;6:1279–1287.
)| false
SchuetzeSM, RubinBP, VernonC et al.. Use of positron emission tomography in localized extremity soft tissue sarcoma treated with neoadjuvant chemotherapy. Cancer2005;103:339–348.
SchuetzeSMRubinBPVernonC. Use of positron emission tomography in localized extremity soft tissue sarcoma treated with neoadjuvant chemotherapy. Cancer2005;103:339–348.
)| false
EaryJF, O’SullivanF, PowitanY et al.. Sarcoma tumor FDG uptake measured by PET and patient outcome: a retrospective analysis. Eur J Nucl Med Mol Imaging2002;29:1149–1154.
EaryJFO’SullivanFPowitanY. Sarcoma tumor FDG uptake measured by PET and patient outcome: a retrospective analysis. Eur J Nucl Med Mol Imaging2002;29:1149–1154.
)| false
PistersPW, PollockRE, LewisVO et al.. Long-term results of prospective trial of surgery alone with selective use of radiation for patients with T1 extremity and trunk soft tissue sarcomas. Ann Surg2007;246:675–681; discussion 681–682.
PistersPWPollockRELewisVO. Long-term results of prospective trial of surgery alone with selective use of radiation for patients with T1 extremity and trunk soft tissue sarcomas. Ann Surg2007;246:675–681; discussion 681–682.
)| false
KraybillWG, HarrisJ, SpiroIJ et al.. Phase II study of neoadjuvant chemotherapy and radiation therapy in the management of high-risk, high-grade, soft tissue sarcomas of the extremities and body wall: Radiation Therapy Oncology Group trial 9514. J Clin Oncol2006;24:619–625.
KraybillWGHarrisJSpiroIJ. Phase II study of neoadjuvant chemotherapy and radiation therapy in the management of high-risk, high-grade, soft tissue sarcomas of the extremities and body wall: Radiation Therapy Oncology Group trial 9514. J Clin Oncol2006;24:619–625.
)| false
DeLaneyTF SI, SuitHD, GebhardtMC et al.. Neoadjuvant chemotherapy and radiotherapy for large extremity soft-tissue sarcomas. Int J Radiat Oncol Biol Phys2003;56:1117–1127.
DeLaneyTF SISuitHDGebhardtMC. Neoadjuvant chemotherapy and radiotherapy for large extremity soft-tissue sarcomas. Int J Radiat Oncol Biol Phys2003;56:1117–1127.
)| false
PistersPW, PatelSR, VarmaDG et al.. Preoperative chemotherapy for stage IIIB extremity soft tissue sarcoma: long-term results from a single institution. J Clin Oncol1997;15:3481–3487.
PistersPWPatelSRVarmaDG. Preoperative chemotherapy for stage IIIB extremity soft tissue sarcoma: long-term results from a single institution. J Clin Oncol1997;15:3481–3487.
)| false
TierneyJF, MosseriV, StewartLA et al.. Adjuvant chemotherapy for soft-tissue sarcoma: review and meta-analysis of the published results of randomised clinical trials. Br J Cancer1995;72:469–475.
TierneyJFMosseriVStewartLA. Adjuvant chemotherapy for soft-tissue sarcoma: review and meta-analysis of the published results of randomised clinical trials. Br J Cancer1995;72:469–475.
)| false
BramwellV, RouesseJ, StewardW et al.. Adjuvant CYVADIC chemotherapy for adult soft tissue sarcoma—reduced local recurrence but no improvement in survival: a study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J Clin Oncol1994;12:1137–1149.
BramwellVRouesseJStewardW. Adjuvant CYVADIC chemotherapy for adult soft tissue sarcoma—reduced local recurrence but no improvement in survival: a study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J Clin Oncol1994;12:1137–1149.
)| false
CormierJN, HuangX, XingY et al.. Cohort analysis of patients with localized, high-risk, extremity soft tissue sarcoma treated at two cancer centers: chemotherapy-associated outcomes. J Clin Oncol2004;22:4567–4574.
CormierJNHuangXXingY. Cohort analysis of patients with localized, high-risk, extremity soft tissue sarcoma treated at two cancer centers: chemotherapy-associated outcomes. J Clin Oncol2004;22:4567–4574.
)| false
FrustaciS, GherlinzoniF, De PaoliA et al.. Adjuvant chemotherapy for adult soft tissue sarcomas of the extremities and girdles: results of the Italian randomized cooperative trial. J Clin Oncol2001;19:1238–1247.
FrustaciSGherlinzoniFDe PaoliA. Adjuvant chemotherapy for adult soft tissue sarcomas of the extremities and girdles: results of the Italian randomized cooperative trial. J Clin Oncol2001;19:1238–1247.
)| false
WollPJ, van GlabbekeM, HohenbergerP et al.. Adjuvant chemotherapy (CT) with doxorubicin and ifosfamide in resected soft tissue sarcoma (STS): interim analysis of a randomised phase III trial [abstract]. J Clin Oncol2007;25(Suppl 1):Abstract 10008.
WollPJvan GlabbekeMHohenbergerP. Adjuvant chemotherapy (CT) with doxorubicin and ifosfamide in resected soft tissue sarcoma (STS): interim analysis of a randomised phase III trial [abstract]. J Clin Oncol2007;25(Suppl 1):Abstract 10008.
)| false
AntmanK, CrowleyJ, BalcerzakS et al.. An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas. J Clin Oncol1993;11:1276–1285.
AntmanKCrowleyJBalcerzakS. An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas. J Clin Oncol1993;11:1276–1285.
)| false
BramwellVH, AndersonD, CharetteML. Doxorubicin-based chemotherapy for the palliative treatment of adult patients with locally advanced or metastatic soft tissue sarcoma. Cochrane Database Syst Rev2003;CD003293.
BramwellVHAndersonDCharetteML. Doxorubicin-based chemotherapy for the palliative treatment of adult patients with locally advanced or metastatic soft tissue sarcoma. Cochrane Database Syst Rev2003;CD003293.
)| false
EdmonsonJ, RyanL, BlumR et al.. Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas. J Clin Oncol1993;11:1269–1275.
EdmonsonJRyanLBlumR. Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas. J Clin Oncol1993;11:1269–1275.
)| false
EliasA, RyanL, SulkesA et al.. Response to mesna, doxorubicin, ifosfamide, and dacarbazine in 108 patients with metastatic or unresectable sarcoma and no prior chemotherapy. J Clin Oncol1989;7:1208–1216.
EliasARyanLSulkesA. Response to mesna, doxorubicin, ifosfamide, and dacarbazine in 108 patients with metastatic or unresectable sarcoma and no prior chemotherapy. J Clin Oncol1989;7:1208–1216.
)| false
LoriganP, VerweijJ, PapaiZ et al.. Phase III trial of two investigational schedules of ifosfamide compared with standard-dose doxorubicin in advanced or metastatic soft tissue sarcoma: a European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study. J Clin Oncol2007;25:3144–3150.
LoriganPVerweijJPapaiZ. Phase III trial of two investigational schedules of ifosfamide compared with standard-dose doxorubicin in advanced or metastatic soft tissue sarcoma: a European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study. J Clin Oncol2007;25:3144–3150.
)| false
SantoroA, TurszT, MouridsenH et al.. Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J Clin Oncol1995;13:1537–1545.
SantoroATurszTMouridsenH. Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J Clin Oncol1995;13:1537–1545.
)| false
ZalupskiM, MetchB, BalcerzakS et al.. Phase III comparison of doxorubicin and dacarbazine given by bolus versus infusion in patients with soft-tissue sarcomas: a Southwest Oncology Group study. J Natl Cancer Inst1991;83:926–932.
ZalupskiMMetchBBalcerzakS. Phase III comparison of doxorubicin and dacarbazine given by bolus versus infusion in patients with soft-tissue sarcomas: a Southwest Oncology Group study. J Natl Cancer Inst1991;83:926–932.
)| false
SiehlJM, ThielE, SchmittelA et al.. Liposomal anthracyclines and ifosfamide in the first line treatment of advanced soft tissue sarcomas: a two cohort phase II study [abstract]. J Clin Oncol2006;24(Suppl 1):Abstract 9563.
SiehlJMThielESchmittelA. Liposomal anthracyclines and ifosfamide in the first line treatment of advanced soft tissue sarcomas: a two cohort phase II study [abstract]. J Clin Oncol2006;24(Suppl 1):Abstract 9563.
)| false
SiehlJM, ThielE, SchmittelA et al.. Ifosfamide/liposomal daunorubicin is a well tolerated and active first-line chemotherapy regimen in advanced soft tissue sarcoma: results of a phase II study. Cancer2005;104:611–617.
SiehlJMThielESchmittelA. Ifosfamide/liposomal daunorubicin is a well tolerated and active first-line chemotherapy regimen in advanced soft tissue sarcoma: results of a phase II study. Cancer2005;104:611–617.
)| false
HensleyML, MakiR, VenkatramanE et al.. Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial. J Clin Oncol2002;20:2824–2831.
HensleyMLMakiRVenkatramanE. Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial. J Clin Oncol2002;20:2824–2831.
)| false
MakiRG, WathenJK, PatelSR et al.. Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002. J Clin Oncol2007;25:2755–2763.
MakiRGWathenJKPatelSR. Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002. J Clin Oncol2007;25:2755–2763.
)| false
LeuKM, OstruszkaLJ, ShewachD et al.. Laboratory and clinical evidence of synergistic cytotoxicity of sequential treament with gemcitabine followed by docetaxel in the treatment of sarcoma. J Clin Oncol2004;22:1706–1712.
LeuKMOstruszkaLJShewachD. Laboratory and clinical evidence of synergistic cytotoxicity of sequential treament with gemcitabine followed by docetaxel in the treatment of sarcoma. J Clin Oncol2004;22:1706–1712.
)| false
BayJO, Ray-CoquardI, FayetteJ et al.. Docetaxel and gemcitabine combination in 133 advanced soft-tissue sarcomas: a retrospective analysis. Int J Cancer2006;119:706–711.
BayJORay-CoquardIFayetteJ. Docetaxel and gemcitabine combination in 133 advanced soft-tissue sarcomas: a retrospective analysis. Int J Cancer2006;119:706–711.
)| false
DileoP, MorganJA, ZahriehD et al.. Gemcitabine and vinorelbine combination chemotherapy for patients with advanced soft tissue sarcomas: results of a phase II trial. Cancer2007;109:1863–1869.
DileoPMorganJAZahriehD. Gemcitabine and vinorelbine combination chemotherapy for patients with advanced soft tissue sarcomas: results of a phase II trial. Cancer2007;109:1863–1869.
)| false
Garcia del MuroX, Lopez-PousaA, MartinJ et al.. A phase II trial of temozolomide as a 6-week, continuous, oral schedule in patients with advanced soft tissue sarcoma: a study by the Spanish Group for Research on Sarcomas. Cancer2005;104:1706–1712.
Garcia del MuroXLopez-PousaAMartinJ. A phase II trial of temozolomide as a 6-week, continuous, oral schedule in patients with advanced soft tissue sarcoma: a study by the Spanish Group for Research on Sarcomas. Cancer2005;104:1706–1712.
)| false
TalbotSM, KeohanML, HesdorfferM et al.. A phase II trial of temozolomide in patients with unresectable or metastatic soft tissue sarcoma. Cancer2003;98:1942–1946.
TalbotSMKeohanMLHesdorfferM. A phase II trial of temozolomide in patients with unresectable or metastatic soft tissue sarcoma. Cancer2003;98:1942–1946.
)| false
Le CesneA, BlayJY, JudsonI et al.. Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) Soft Tissue and Bone Sarcoma Group trial. J Clin Oncol2005;23:576–584.
Le CesneABlayJYJudsonI. Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) Soft Tissue and Bone Sarcoma Group trial. J Clin Oncol2005;23:576–584.
)| false
Garcia-CarboneroR, SupkoJG, ManolaJ et al.. Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy. J Clin Oncol2004;22:1480–1490.
Garcia-CarboneroRSupkoJGManolaJ. Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy. J Clin Oncol2004;22:1480–1490.
)| false
Garcia-CarboneroR, SupkoJG, MakiRG et al.. Ecteinascidin-743 (ET-743) for chemotherapy-naive patients with advanced soft tissue sarcomas: multicenter phase II and pharmacokinetic study. J Clin Oncol2005;23:5484–5492.
Garcia-CarboneroRSupkoJGMakiRG. Ecteinascidin-743 (ET-743) for chemotherapy-naive patients with advanced soft tissue sarcomas: multicenter phase II and pharmacokinetic study. J Clin Oncol2005;23:5484–5492.
)| false
YovineA, RiofrioM, BlayJY et al.. Phase II study of ecteinascidin-743 in advanced pretreated soft tissue sarcoma patients. J Clin Oncol2004;22:890–899.
YovineARiofrioMBlayJY. Phase II study of ecteinascidin-743 in advanced pretreated soft tissue sarcoma patients. J Clin Oncol2004;22:890–899.
)| false
LaverdiereC, KolbEA, SupkoJG et al.. Phase II study of ecteinascidin 743 in heavily pretreated patients with recurrent osteosarcoma. Cancer2003;98:832–840.
LaverdiereCKolbEASupkoJG. Phase II study of ecteinascidin 743 in heavily pretreated patients with recurrent osteosarcoma. Cancer2003;98:832–840.
)| false
IsselsRD, LindnerLH, WustP et al.. Regional hyperthermia (RHT) improves response and survival when combined with systemic chemotherapy in the management of locally advanced, high grade soft tissue sarcomas (STS) of the extremities, the body wall and the abdomen: a phase III randomised pros [abstract]. J Clin Oncol2007;25(Suppl 1):Abstract 10009.
IsselsRDLindnerLHWustP. Regional hyperthermia (RHT) improves response and survival when combined with systemic chemotherapy in the management of locally advanced, high grade soft tissue sarcomas (STS) of the extremities, the body wall and the abdomen: a phase III randomised pros [abstract]. J Clin Oncol2007;25(Suppl 1):Abstract 10009.
)| false
GrunhagenDJ, BrunsteinF, ten HagenTL et al.. TNF-based isolated limb perfusion: a decade of experience with antivascular therapy in the management of locally advanced extremity soft tissue sarcomas. Cancer Treat Res2004;120:65–79.
GrunhagenDJBrunsteinFten HagenTL. TNF-based isolated limb perfusion: a decade of experience with antivascular therapy in the management of locally advanced extremity soft tissue sarcomas. Cancer Treat Res2004;120:65–79.
)| false
GrunhagenDJ, de WiltJH, GravelandWJ et al.. Outcome and prognostic factor analysis of 217 consecutive isolated limb perfusions with tumor necrosis factor-alpha and melphalan for limb-threatening soft tissue sarcoma. Cancer2006;106:1776–1784.
GrunhagenDJde WiltJHGravelandWJ. Outcome and prognostic factor analysis of 217 consecutive isolated limb perfusions with tumor necrosis factor-alpha and melphalan for limb-threatening soft tissue sarcoma. Cancer2006;106:1776–1784.
)| false
LewisJJ, LeungD, CasperES et al.. Multifactorial analysis of long-term follow-up (more than 5 years) of primary extremity sarcoma. Arch Surg1999;134:190–194.
LewisJJLeungDCasperES. Multifactorial analysis of long-term follow-up (more than 5 years) of primary extremity sarcoma. Arch Surg1999;134:190–194.
)| false
FlemingJB, CantorSB, VarmaDG et al.. Utility of chest computed tomography for staging in patients with T1 extremity soft tissue sarcomas. Cancer2001;92:863–868.
FlemingJBCantorSBVarmaDG. Utility of chest computed tomography for staging in patients with T1 extremity soft tissue sarcomas. Cancer2001;92:863–868.
)| false
SingerS, AntmanK, CorsonJM, EberleinTJ. Long-term salvageability for patients with locally recurrent soft-tissue sarcomas. Arch Surg1992;127:548–553; discussion 553–544. References 108–127 are cited in the section on “Retroperitoneal/Intra-Abdominal Soft Tissue Sarcomas,” and are available in the version of these guidelines online at www.NCCN. org.
SingerSAntmanKCorsonJMEberleinTJ. Long-term salvageability for patients with locally recurrent soft-tissue sarcomas. Arch Surg1992;127:548–553; discussion 553–544. References 108–127 are cited in the section on “Retroperitoneal/Intra-Abdominal Soft Tissue Sarcomas,” and are available in the version of these guidelines online at www.NCCN. org.
)| false
DemetriGD, von MehrenM, BlankeCD et al.. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med2002;347:472–480.
DemetriGDvon MehrenMBlankeCD. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med2002;347:472–480.
)| false
BlankeCD, DemetriGD, von MehrenM et al.. Long-term results from a randomized phase II trial of standard-versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J Clin Oncol2008;26:620–625.
BlankeCDDemetriGDvon MehrenM. Long-term results from a randomized phase II trial of standard-versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J Clin Oncol2008;26:620–625.
)| false
BlankeCD, RankinC, DemetriGD et al.. Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J Clin Oncol2008;26:626–632.
BlankeCDRankinCDemetriGD. Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J Clin Oncol2008;26:626–632.
)| false
DagherR, CohenM, WilliamsG et al.. Approval summary: imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors. Clin Cancer Res2002;8:3034–3038.
DagherRCohenMWilliamsG. Approval summary: imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors. Clin Cancer Res2002;8:3034–3038.
)| false
HeinrichMC, CorlessCL, DemetriGD et al.. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol2003;21:4342–4349.
HeinrichMCCorlessCLDemetriGD. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol2003;21:4342–4349.
)| false
Debiec-RychterM, DumezH, JudsonI et al.. Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer2004;40:689–695.
Debiec-RychterMDumezHJudsonI. Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer2004;40:689–695.
)| false
HeinrichMC, OwzarK, CorlessCL et al.. Correlation of kinase genotype and clinical outcome in the North American Intergroup phase III trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group. J Clin Oncol2008;26:5360–5367.
HeinrichMCOwzarKCorlessCL. Correlation of kinase genotype and clinical outcome in the North American Intergroup phase III trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group. J Clin Oncol2008;26:5360–5367.
)| false
ZalcbergJR, VerweijJ, CasaliPG et al.. Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg. Eur J Cancer2005;41:1751–1757.
ZalcbergJRVerweijJCasaliPG. Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg. Eur J Cancer2005;41:1751–1757.
)| false
Debiec-RychterM, SciotR, Le CesneA et al.. KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. Eur J Cancer2006;42:1093–1103.
Debiec-RychterMSciotRLe CesneA. KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. Eur J Cancer2006;42:1093–1103.
)| false
Gastrointestinal stromal tumor meta-analysis group comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors: a meta-analysis of 1,640 Patients. J Clin Oncol2010;28:1247–1253.
Gastrointestinal stromal tumor meta-analysis group comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors: a meta-analysis of 1,640 Patients. J Clin Oncol2010;28:1247–1253.
)| false
EisenbergBL, HarrisJ, BlankeCD et al.. Phase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor (GIST): early results of RTOG 0132/ACRIN 6665. J Surg Oncol2009;99:42–47.
EisenbergBLHarrisJBlankeCD. Phase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor (GIST): early results of RTOG 0132/ACRIN 6665. J Surg Oncol2009;99:42–47.
)| false
McAuliffeJC, HuntKK, LazarAJ et al.. A randomized, phase II study of preoperative plus postoperative imatinib in GIST: evidence of rapid radiographic response and temporal induction of tumor cell apoptosis. Ann Surg Oncol2009;16:910–919.
McAuliffeJCHuntKKLazarAJ. A randomized, phase II study of preoperative plus postoperative imatinib in GIST: evidence of rapid radiographic response and temporal induction of tumor cell apoptosis. Ann Surg Oncol2009;16:910–919.
)| false
EisenbergBL, JudsonI. Surgery and imatinib in the management of GIST: emerging approaches to adjuvant and neoadjuvant therapy. Ann Surg Oncol2004;11:465–475.
EisenbergBLJudsonI. Surgery and imatinib in the management of GIST: emerging approaches to adjuvant and neoadjuvant therapy. Ann Surg Oncol2004;11:465–475.
)| false
DeMatteoRP, LewisJJ, LeungD et al.. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg2000;231:51–58.
DeMatteoRPLewisJJLeungD. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg2000;231:51–58.
)| false
DematteoRP, AntonescuCR, ChadaramV et al.. Adjuvant imatinib mesylate in patients with primary high risk gastrointestinal stromal tumor (GIST) following complete resection: safety results from the U.S. Intergroup phase II trial ACOSOG Z9000 [abstract]. J Clin Oncol2005;23(Suppl 1):Abstract 9009.
DematteoRPAntonescuCRChadaramV. Adjuvant imatinib mesylate in patients with primary high risk gastrointestinal stromal tumor (GIST) following complete resection: safety results from the U.S. Intergroup phase II trial ACOSOG Z9000 [abstract]. J Clin Oncol2005;23(Suppl 1):Abstract 9009.
)| false
TrentJC, PatelSS, ZhangJ et al.. Rare incidence of congestive heart failure in gastrointestinal stromal tumor and other sarcoma patients receiving imatinib mesylate. Cancer2010;116:184–192.
TrentJCPatelSSZhangJ. Rare incidence of congestive heart failure in gastrointestinal stromal tumor and other sarcoma patients receiving imatinib mesylate. Cancer2010;116:184–192.
)| false
BenjaminRS, Debiec-RychterM, Le CesneA et al.. Gastrointestinal stromal tumors II: medical oncology and tumor response assessment. Semin Oncol2009;36:302–311.
BenjaminRSDebiec-RychterMLe CesneA. Gastrointestinal stromal tumors II: medical oncology and tumor response assessment. Semin Oncol2009;36:302–311.
)| false
MaledduA, PantaleoMA, NanniniM et al.. Mechanisms of secondary resistance to tyrosine kinase inhibitors in gastrointestinal stromal tumours (review). Oncol Rep2009;21:1359–1366.
MaledduAPantaleoMANanniniM. Mechanisms of secondary resistance to tyrosine kinase inhibitors in gastrointestinal stromal tumours (review). Oncol Rep2009;21:1359–1366.
)| false
HeinrichMC, McArthurGA, DemetriGD et al.. Clinical and molecular studies of the effect of imatinib on advanced aggressive fibromatosis (desmoid tumor). J Clin Oncol2006;24:1195–1203.
HeinrichMCMcArthurGADemetriGD. Clinical and molecular studies of the effect of imatinib on advanced aggressive fibromatosis (desmoid tumor). J Clin Oncol2006;24:1195–1203.
)| false
DemetriGD, van OosteromAT, GarrettCR et al.. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet2006;368:1329–1338.
DemetriGDvan OosteromATGarrettCR. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet2006;368:1329–1338.
)| false
GeorgeS, BlayJY, CasaliPG et al.. Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure. Eur J Cancer2009;45:1959–1968.
GeorgeSBlayJYCasaliPG. Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure. Eur J Cancer2009;45:1959–1968.
)| false
ChuD, LacoutureME, WeinerE, WuS. Risk of hand-foot skin reaction with the multitargeted kinase inhibitor sunitinib in patients with renal cell and non-renal cell carcinoma: a meta-analysis. Clin Genitourin Cancer2009;7:11–19.
ChuDLacoutureMEWeinerEWuS. Risk of hand-foot skin reaction with the multitargeted kinase inhibitor sunitinib in patients with renal cell and non-renal cell carcinoma: a meta-analysis. Clin Genitourin Cancer2009;7:11–19.
)| false
ZhuX, StergiopoulosK, WuS. Risk of hypertension and renal dysfunction with an angiogenesis inhibitor sunitinib: systematic review and meta-analysis. Acta Oncol2009;48:9–17.
ZhuXStergiopoulosKWuS. Risk of hypertension and renal dysfunction with an angiogenesis inhibitor sunitinib: systematic review and meta-analysis. Acta Oncol2009;48:9–17.
)| false
TorinoF, CorselloSM, LongoR et al.. Hypothyroidism related to tyrosine kinase inhibitors: an emerging toxic effect of targeted therapy. Nat Rev Clin Oncol2009;6:219–228.
TorinoFCorselloSMLongoR. Hypothyroidism related to tyrosine kinase inhibitors: an emerging toxic effect of targeted therapy. Nat Rev Clin Oncol2009;6:219–228.
)| false
SepePS, MopartyB, PitmanMB et al.. EUS-guided FNA for the diagnosis of GI stromal cell tumors: sensitivity and cytologic yield. Gastrointest Endosc2009;70:254–261.
SepePSMopartyBPitmanMB. EUS-guided FNA for the diagnosis of GI stromal cell tumors: sensitivity and cytologic yield. Gastrointest Endosc2009;70:254–261.
)| false
Van Den AbbeeleAD, BadawiRD, ManolaJ et al.. Effects of cessation of imatinib mesylate (IM) therapy in patients (pts) with IM-refractory gastrointestinal stromal tumors (GIST) as visualized by FDG-PET scanning [abstract]. J Clin Oncol2004;22(Suppl 1):Abstract 3012.
Van Den AbbeeleADBadawiRDManolaJ. Effects of cessation of imatinib mesylate (IM) therapy in patients (pts) with IM-refractory gastrointestinal stromal tumors (GIST) as visualized by FDG-PET scanning [abstract]. J Clin Oncol2004;22(Suppl 1):Abstract 3012.
)| false
BlayJY, Le CesneA, Ray-CoquardI et al.. Prospective multicentric randomized phase III study of imatinib in patients with advanced gastrointestinal stromal tumors comparing interruption versus continuation of treatment beyond 1 year: the French Sarcoma Group. J Clin Oncol2007;25:1107–1113.
BlayJYLe CesneARay-CoquardI. Prospective multicentric randomized phase III study of imatinib in patients with advanced gastrointestinal stromal tumors comparing interruption versus continuation of treatment beyond 1 year: the French Sarcoma Group. J Clin Oncol2007;25:1107–1113.
)| false
GoldJS, GonenM, GutierrezA et al.. Development and validation of a prognostic nomogram for recurrence-free survival after complete surgical resection of localised primary gastrointestinal stromal tumour: a retrospective analysis. Lancet Oncol2009;10:1045–1052.
GoldJSGonenMGutierrezA. Development and validation of a prognostic nomogram for recurrence-free survival after complete surgical resection of localised primary gastrointestinal stromal tumour: a retrospective analysis. Lancet Oncol2009;10:1045–1052.
)| false
RautCP, PosnerM, DesaiJ et al.. Surgical management of advanced gastrointestinal stromal tumors after treatment with targeted systemic therapy using kinase inhibitors. J Clin Oncol2006;24:2325–2331.
RautCPPosnerMDesaiJ. Surgical management of advanced gastrointestinal stromal tumors after treatment with targeted systemic therapy using kinase inhibitors. J Clin Oncol2006;24:2325–2331.
)| false
WiebeL, KaszaKE, MakiRG et al.. Activity of sorafenib (SOR) in patients (pts) with imatinib (IM) and sunitinib (SU)-resistant (RES) gastrointestinal stromal tumors (GIST): a phase II trial of the University of Chicago Phase II Consortium [abstract]. J Clin Oncol2008;26(Suppl 1):Abstract 10502.
WiebeLKaszaKEMakiRG. Activity of sorafenib (SOR) in patients (pts) with imatinib (IM) and sunitinib (SU)-resistant (RES) gastrointestinal stromal tumors (GIST): a phase II trial of the University of Chicago Phase II Consortium [abstract]. J Clin Oncol2008;26(Suppl 1):Abstract 10502.
)| false
BlayJY, CasaliPG, ReichardtP et al.. A phase I study of nilotinib alone and in combination with imatinib in patients with imatinib-resistant gastrointestinal stromal tumors (GIST): study update [abstract]. J Clin Oncol2008;26(Suppl 1):Abstract 10553.
BlayJYCasaliPGReichardtP. A phase I study of nilotinib alone and in combination with imatinib in patients with imatinib-resistant gastrointestinal stromal tumors (GIST): study update [abstract]. J Clin Oncol2008;26(Suppl 1):Abstract 10553.
)| false
DemetriGD, Lo RussoP, MacPhersonIR et al.. Phase I dose-escalation and pharmacokinetic study of dasatinib in patients with advanced solid tumors. Clin Cancer Res2009;15:6232–6240.
DemetriGDLo RussoPMacPhersonIR. Phase I dose-escalation and pharmacokinetic study of dasatinib in patients with advanced solid tumors. Clin Cancer Res2009;15:6232–6240.
)| false
FumagalliE, CocoP, MorosiC et al.. Rechallenge with imatinib in GIST patients resistant to second or third line therapy. Presented at the 2009 Connective Tissue Oncology Society 15th Annual Meeting; November 5–7, 2009; Miami Beach, Florida. Abstract 39404. References 174–201 are cited in the section on “Desmoid Tumors (Fibromatoses),” and are available in the version of these guidelines online at www.NCCN.org.
FumagalliECocoPMorosiC. Rechallenge with imatinib in GIST patients resistant to second or third line therapy. Presented at the 2009 Connective Tissue Oncology Society 15th Annual Meeting; November 5–7, 2009; Miami Beach, Florida. Abstract 39404. References 174–201 are cited in the section on “Desmoid Tumors (Fibromatoses),” and are available in the version of these guidelines online at www.NCCN.org.
)| false
